Reduced dosimetry using NLME

On-treatment dosimetry data are essential to calculate absorbed dose to provide safe and efficacious treatment in RLTs. Dosimetry calculation requires quantitative imaging at multiple time points post-injection of the RLT per cycle of treatment. The number of the required quantitative imaging time points, while maintaining the quality and accuracy of the dosimetry data, can be reduced for the subsequent cycles, hence reduced patient burden and study cost, by applying the knowledge from the first therapy cycle via population reduced dosimetry NLME modeling approach. Work performed at Novartis and Astra Zeneca.